## Living Cell Technologies Limited

**ACN:** 104 028 042
**ASX:** LCT
**OTCQX:** LVCLY

**ASX ANNOUNCEMENT**

# Appendix 4C Quarterly Cash Flow Report 30 June 2015

**27 July 2015 – Sydney, Australia & Auckland, New Zealand –** Living Cell Technologies Limited today released its cash flow report for the quarter ended 30 June 2015. The Appendix 4C is attached. The company ended the quarter with a cash balance of $5,144,027 compared to $6,349,884 in the previous quarter. The decrease is due to normal operating costs, PET scanning and the cost of continuing to monitor clinical trial patients.

Post implant monitoring and PET scanning of patients in the Phase I/IIa clinical trial in New Zealand of NTCELL® for the treatment of Parkinson's disease continued during the quarter. The trial results were announced on 15 June 2015 and presented at the International Congress of Movement Disorders and Parkinson's Disease, San Diego, USA. The clinical trial met its primary endpoint of safety, showing NTCELL implantation was well tolerated, with no adverse events considered to be related to NTCELL. NTCELL implantation also improved clinical features of Parkinson's disease in the four patients studied, as measured by validated neurological rating scales and questionnaires, with the improvement sustained at 26 weeks post-implant.

Net operating cash flow in the quarter was $(1,320,618) compared to $(695,388) in the previous quarter. Receipts from customers were $175,186 (previous quarter $146,219) reflecting the finalisation of clinical trial monitoring services provided to the joint venture company. Operating payments were $1,620,882 compared to $938,302 in the previous quarter. This increase is primarily due to PET scanning of the last two patients and clinical trial monitoring costs.

**– Ends –**

**For further information:** www.lctglobal.com


| **At the company:** | **Media enquires:** |
|---|---|
| Ken Taylor<br>Chief Executive<br>Tel: +64 9 276 2690<br>Mobile: +64 21 796000<br>ktaylor@lctglobal.com | Rachael Joel<br>Botica Butler Raudon Partners<br>Tel: +64 9 303 3862<br>Mobile: +64 21 403 504<br>rachaelj@botica.co.nz |


## About Living Cell Technologies

Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which restore function using naturally occurring cells.

LCT's lead product NTCELL® is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory producing factors to promote new central nervous system growth and repair disease induced nerve degeneration.

The Phase I/IIa NTCELL clinical trial in New Zealand for the treatment of Parkinson's disease met the primary endpoint of safety and showed encouraging clinical efficacy improvements. Results from this trial will be used to design a larger Phase IIb trial to evaluate its potential as a disease-modifying treatment for patients with Parkinson's disease. It has the potential to be used in a number of other central nervous system indications such as Huntington's, Alzheimer's and motor neurone diseases.

LCT's proprietary encapsulation technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system.

LCT holds a 50% interest in Diatranz Otsuka Limited which is developing a cell therapy for type 1 diabetes.

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand.

For more information visit www.lctglobal.com or follow @lctglobal on Twitter

**Forward-looking statements**

This document may contain certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialisation of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.